• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在具有多个终点的临床试验中实施最优分配

Implementing Optimal Allocation in Clinical Trials with Multiple Endpoints.

作者信息

Wang Lu, Chen Yong, Zhu Hongjian

机构信息

Department of Biostatistics, University of Texas Health Science Center School of Public Health at Houston, 1200 Pressler St, Houston, Texas 77030, USA.

Department of Biostatistics and Epidemiology, University of Pennsylvania, 210 Blockley Hall, 423 Guardian Drive, Philadelphia, PA 19104.

出版信息

J Stat Plan Inference. 2017 Mar;182:88-99. doi: 10.1016/j.jspi.2016.09.002. Epub 2016 Oct 7.

DOI:10.1016/j.jspi.2016.09.002
PMID:28529406
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5435386/
Abstract

Modern clinical trials are often complex, with multiple competing objectives and multiple endpoints. Such trials should be both ethical and efficient. In this paper, we overcome the obstacles introduced by the large number of unknown parameters and the possible correlations between the multiple endpoints. We obtain the optimal allocation proportions for the following two optimization problems: (1) maximizing the power of the test of homogeneity with a fixed sample size, and (2) minimizing the expected weighted number of failures with a fixed power. Further, we implement these optimal allocations through response-adaptive randomization procedures. Our theoretical results provide the foundation for the implementation and further investigation of the procedure, and our numerical studies demonstrate its ability to achieve diverse objectives.

摘要

现代临床试验通常很复杂,有多个相互竞争的目标和多个终点。此类试验应兼具伦理道德性和高效性。在本文中,我们克服了大量未知参数以及多个终点之间可能存在的相关性所带来的障碍。我们针对以下两个优化问题获得了最优分配比例:(1)在固定样本量的情况下最大化齐性检验的功效,以及(2)在固定功效的情况下最小化预期加权失败次数。此外,我们通过响应自适应随机化程序来实施这些最优分配。我们的理论结果为该程序的实施和进一步研究提供了基础,并且我们的数值研究证明了其实现不同目标的能力。

相似文献

1
Implementing Optimal Allocation in Clinical Trials with Multiple Endpoints.在具有多个终点的临床试验中实施最优分配
J Stat Plan Inference. 2017 Mar;182:88-99. doi: 10.1016/j.jspi.2016.09.002. Epub 2016 Oct 7.
2
Maximizing power and minimizing treatment failures in clinical trials.在临床试验中最大化检验效能并最小化治疗失败情况。
Clin Trials. 2004;1(2):141-7. doi: 10.1191/1740774504cn016oa.
3
A simulation study for comparing testing statistics in response-adaptive randomization.一种用于比较响应自适应随机化中检验统计量的仿真研究。
BMC Med Res Methodol. 2010 Jun 5;10:48. doi: 10.1186/1471-2288-10-48.
4
Doubly adaptive biased coin design to improve Bayesian clinical trials with time-to-event endpoints.双自适应有偏硬币设计,提高贝叶斯临床试验中时间相关终点的效率。
Stat Med. 2024 Apr 30;43(9):1743-1758. doi: 10.1002/sim.10047. Epub 2024 Feb 22.
5
Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.COVID-19 住院成人患者使用伊马替尼的安全性和疗效:一项随机对照试验研究方案的结构化总结。
Trials. 2020 Oct 28;21(1):897. doi: 10.1186/s13063-020-04819-9.
6
Statistical inference for response adaptive randomization procedures with adjusted optimal allocation proportions.具有调整后最优分配比例的响应自适应随机化程序的统计推断。
J Biopharm Stat. 2017;27(5):732-740. doi: 10.1080/10543406.2016.1269780. Epub 2017 Jan 19.
7
Optimal and ethical designs for hypothesis testing in multi-arm exponential trials.多臂指数试验中假设检验的最优和伦理设计。
Stat Med. 2021 May 20;40(11):2578-2603. doi: 10.1002/sim.8919. Epub 2021 Mar 9.
8
Two-stage response adaptive randomization designs for multi-arm trials with binary outcome.两阶段反应适应性随机分组设计在多臂二分类临床试验中的应用。
J Biopharm Stat. 2024 Jul 3;34(4):526-538. doi: 10.1080/10543406.2023.2234028. Epub 2023 Jul 15.
9
Implementing unequal randomization in clinical trials with heterogeneous treatment costs.在治疗费用存在差异的临床试验中实施不均衡随机化。
Stat Med. 2019 Jul 20;38(16):2905-2927. doi: 10.1002/sim.8160. Epub 2019 May 3.
10
Optimal sample size allocation for two-arm superiority and non-inferiority trials with binary endpoints.两臂优效和非劣效试验中二分类结局的最优样本量分配。
Pharm Stat. 2024 Sep-Oct;23(5):678-686. doi: 10.1002/pst.2375. Epub 2024 Mar 12.

引用本文的文献

1
Response adaptive randomization procedures in seamless phase II/III clinical trials.无缝二期/三期临床试验中的反应适应性随机化程序。
J Biopharm Stat. 2020;30(1):3-17. doi: 10.1080/10543406.2019.1657439. Epub 2019 Aug 27.

本文引用的文献

1
Optimal response-adaptive designs for normal responses.针对正态响应的最优响应自适应设计。
Biom J. 2009 Feb;51(1):193-202. doi: 10.1002/bimj.200810500.
2
A graphical approach to sequentially rejective multiple test procedures.一种用于序贯拒绝多重检验程序的图形方法。
Stat Med. 2009 Feb 15;28(4):586-604. doi: 10.1002/sim.3495.
3
The non-central chi2- and F-distributions and their applications.非中心卡方分布和F分布及其应用。
Biometrika. 1949 Jun;36(Pt. 1-2):202-32.
4
Power and sample size when multiple endpoints are considered.考虑多个终点时的检验效能和样本量。
Pharm Stat. 2007 Jul-Sep;6(3):161-70. doi: 10.1002/pst.301.
5
Response-adaptive randomization for clinical trials with continuous outcomes.具有连续结果的临床试验的响应自适应随机化
Biometrics. 2006 Jun;62(2):562-9. doi: 10.1111/j.1541-0420.2005.00496.x.
6
Maximizing power and minimizing treatment failures in clinical trials.在临床试验中最大化检验效能并最小化治疗失败情况。
Clin Trials. 2004;1(2):141-7. doi: 10.1191/1740774504cn016oa.
7
Neutrophil elastase inhibition in acute lung injury: results of the STRIVE study.急性肺损伤中中性粒细胞弹性蛋白酶抑制作用:STRIVE研究结果
Crit Care Med. 2004 Aug;32(8):1695-702. doi: 10.1097/01.ccm.0000133332.48386.85.
8
Optimal adaptive designs for binary response trials.二元响应试验的最优适应性设计。
Biometrics. 2001 Sep;57(3):909-13. doi: 10.1111/j.0006-341x.2001.00909.x.
9
A comparison of urn designs for randomized clinical trials of K > 2 treatments.K>2种治疗方法的随机临床试验的瓮设计比较。
J Biopharm Stat. 2000 Feb;10(1):93-107. doi: 10.1081/BIP-100101016.
10
Group sequential tests for bivariate response: interim analyses of clinical trials with both efficacy and safety endpoints.双变量反应的序贯检验:具有疗效和安全性终点的临床试验的期中分析。
Biometrics. 1993 Sep;49(3):741-52.